IN2014DN06942A - - Google Patents

Info

Publication number
IN2014DN06942A
IN2014DN06942A IN6942DEN2014A IN2014DN06942A IN 2014DN06942 A IN2014DN06942 A IN 2014DN06942A IN 6942DEN2014 A IN6942DEN2014 A IN 6942DEN2014A IN 2014DN06942 A IN2014DN06942 A IN 2014DN06942A
Authority
IN
India
Prior art keywords
crystal form
methyltetrahydrofolate
salt
angles
ray diffraction
Prior art date
Application number
Inventor
Zheqing Wang
Yongzhi Cheng
Heng Huang
Huizhen Li
Original Assignee
Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201210019038.4A external-priority patent/CN102584826B/en
Priority claimed from CN201210018941.9A external-priority patent/CN102775407B/en
Priority claimed from CN201210125133.2A external-priority patent/CN102702200B/en
Application filed by Lianyungang Jinkang Hexin Pharmaceutical Co Ltd filed Critical Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
Publication of IN2014DN06942A publication Critical patent/IN2014DN06942A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B30/00—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions
    • C30B30/06—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions using mechanical vibrations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Disclosed is a crystal form of (6S) 5 methyltetrahydrofolate salt and a method for preparing same. The crystal form is: C form of the crystal form of (6S) 5 methyltetrahydrofolate calcium salt the X ray diffraction pattern thereof having diffraction peaks at the 2? angles of 6.3±0.2 and 19.2±0.2; or the crystal form of (6S) 5 methyltetrahydrofolate strontium salt the X ray diffraction pattern thereof having diffraction peaks at the 2? angles of 6.5±0.2 and 22.0±0.2. The crystal form of (6S) 5 methyltetrahydrofolate salt in the present invention has advantages such as excellent physicochemical properties good stability high purity good reproducibility and being more suitable for production on an industrial scale.
IN6942DEN2014 2012-01-20 2012-12-17 IN2014DN06942A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201210019038.4A CN102584826B (en) 2012-01-20 2012-01-20 (6S)-5-methyl tetrahydrofolate crystal form and preparation method thereof
CN201210018941.9A CN102775407B (en) 2012-01-20 2012-01-20 Stable unformed 5-methyltetrahydrofolate salt and preparation method thereof
CN201210125133.2A CN102702200B (en) 2012-04-25 2012-04-25 (6RS)-5-methyl tetrahydrofolate calcium salt crystal form and preparation process thereof
PCT/CN2012/086794 WO2013107236A1 (en) 2012-01-20 2012-12-17 Crystal form of (6s)-5-methyltetrahydrofolate salt and method for preparing same

Publications (1)

Publication Number Publication Date
IN2014DN06942A true IN2014DN06942A (en) 2015-04-10

Family

ID=48798580

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6942DEN2014 IN2014DN06942A (en) 2012-01-20 2012-12-17

Country Status (11)

Country Link
US (1) US9150982B2 (en)
EP (1) EP2805952B1 (en)
JP (1) JP6166736B2 (en)
KR (1) KR101694710B1 (en)
BR (1) BR112014017939A2 (en)
CA (1) CA2861891C (en)
ES (1) ES2715599T3 (en)
HR (1) HRP20190317T1 (en)
IN (1) IN2014DN06942A (en)
PL (1) PL2805952T3 (en)
WO (1) WO2013107236A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193778A1 (en) 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium
NZ730790A (en) * 2014-09-04 2024-02-23 Lianyungang Jinkang Hexin Pharmaceutical Co Ltd Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
CN110475778A (en) * 2017-03-31 2019-11-19 默克专利股份有限公司 5- methyl-(6S)-tetrahydrofolic acid crystallization sodium salt
RU2019134064A (en) * 2017-03-31 2021-04-30 Мерк Патент Гмбх CRYSTALLINE SODIUM SALT OF 5-METHYL- (6S) -TETRAHYDROPHOLIC ACID
WO2020007841A1 (en) * 2018-07-06 2020-01-09 Merck Patent Gmbh Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and l-valine ethyl ester

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
CH693905A5 (en) * 1999-04-15 2004-04-15 Eprova Ag Stable crystalline salts of 5-methyl tetrahydrofolic acid.
DE10137017A1 (en) * 2001-07-30 2003-02-20 Basf Ag Crystallization process for the adjustment of small particles
RU2007145207A (en) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) ESOMEPRAZOL STRONGTED SALT, METHOD FOR PRODUCING IT AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
CN100336814C (en) 2005-11-23 2007-09-12 天津大学 Method for preparing spherical crystal lactochrome utilizing solvent supersonic synergetic effect
KR100878140B1 (en) * 2007-01-29 2009-01-12 한미약품 주식회사 Atorvastatin strontium salt or hydrate thereof, and pharmaceutical composition comprising same
CH698729B1 (en) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stable crystalline (6S) -N (5) -methyl-5, 6,7,8-tetrahydrofolic acid.
CN102775407B (en) 2012-01-20 2015-08-05 连云港金康医药科技有限公司 Stable unformed 5-methyltetrahydrofolate salt and preparation method thereof
CN102702200B (en) 2012-04-25 2014-11-12 连云港金康和信药业有限公司 (6RS)-5-methyl tetrahydrofolate calcium salt crystal form and preparation process thereof
CN102584826B (en) 2012-01-20 2015-04-29 连云港金康医药科技有限公司 (6S)-5-methyl tetrahydrofolate crystal form and preparation method thereof

Also Published As

Publication number Publication date
BR112014017939A8 (en) 2017-07-11
EP2805952A1 (en) 2014-11-26
KR101694710B1 (en) 2017-01-10
BR112014017939A2 (en) 2021-05-25
JP2015506941A (en) 2015-03-05
EP2805952B1 (en) 2019-02-06
US9150982B2 (en) 2015-10-06
US20150018357A1 (en) 2015-01-15
HRP20190317T1 (en) 2019-05-03
CA2861891C (en) 2018-06-19
KR20140113740A (en) 2014-09-24
JP6166736B2 (en) 2017-07-19
PL2805952T3 (en) 2019-05-31
CA2861891A1 (en) 2013-07-25
EP2805952A4 (en) 2015-07-01
ES2715599T3 (en) 2019-06-05
WO2013107236A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
IN2014DN06942A (en)
PH12019500681A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
WO2015040640A3 (en) An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
UA116991C2 (en) Methods for synthesizing amatoxin building block and amatoxins
WO2011107186A3 (en) Compounds for electronic devices
NZ743374A (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
WO2015008218A3 (en) Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
MX336865B (en) Imidazopyridazines as akt kinase inhibitors.
UA118550C2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
TN2012000435A1 (en) Agomelatine hydrochloride hydrate and preparation thereof
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
MX359069B (en) Salt and crystal forms of plk-4 inhibitor.
AU2014371081A1 (en) Polyoxalates and a Process for the Production Thereof
MX2016002718A (en) KETO-IMIDAZOPYRIDINE DERIVATIVES AS RORc MODULATORS.
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
AU2018374682A1 (en) Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, and crystalline forms thereof
NZ720340A (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
UA113988C2 (en) METHOD OF STABILIZATION OF BETA-SEMI-HYDRAULIC Plaster plaster
MX349752B (en) Process for preparing 3-methylsulfonylpropionitrile.
SG10201909235VA (en) High purity synthetic fluorite, process for preparing the same and apparatus therefor
TW201613944A (en) Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same
MX2016011314A (en) Process for the preparation of precipitated silicas, precipitated silicas and their uses, in particular for the reinforcement of polymers.
WO2015087343A3 (en) An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof